Biotech entity
The clearest coverage concentration is pharma: 8 of 11 stories, with the rest divided among 3 other categories. They are less corroborated than the beat average, carrying 2.6 original sources each against 3.5 for the same window. That works out to roughly 0.4 stories per week across a 183-day span. The busiest single day carried 3.
Last mentioned: Aug 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 9 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 8 of 11 stories, with the rest divided among 3 other categories. They are less corroborated than the beat average, carrying 2.6 original sources each against 3.5 for the same window. That works out to roughly 0.4 stories per week across a 183-day span. The busiest single day carried 3. Against the same-window beat baseline of 16% negative, this entity's 18% share is more negative. The 6.3 average consequence score is above the beat benchmark of 6.1 in the same window. AstraZeneca is the most frequent co-covered peer, appearing in 2 of the 11 tracked stories. Bristol Myers Squibb appears in 11 tracked Biotech stories published from February 19, 2026 through August 20, 2026.
Computed from the 11 stories linked to this entity, with beat comparisons drawn from all 753 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bristol Myers Squibb. Shared-story counts are live from our verified record — not editorial picks.
Litigation Filed
Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Partnership Termination
BMS and Nektar officially end their global clinical development collaboration.
Phase 3 Failure
Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
BMS Partnership
Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.
Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Source: edition.cnn.com · freerepublic.com
The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Source: eadt.co.uk · chardandilminsternews.co.uk
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches.
Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
LOTTE Biologics is set to engage with global pharmaceutical leaders at DCAT Week 2026 in New York, aiming to secure strategic partnerships and showcase its expanding CDMO capabilities. The move underscores the company's aggressive push to become a top-tier global contract manufacturer by leveraging its Syracuse and Songdo facilities.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.
Source: fool.com · insidermonkey.com
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Source: Seeking Alpha · Seeking Alpha
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Source: weeklyvoice.com · admin (in)
Bristol Myers Squibb is linked from 11 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
